title: Increasing CNS noradrenaline reduces EAE severity.
abstract: The endogenous neurotransmitter noradrenaline (NA) is known to exert potent anti-inflammatory effects in glial cells, as well as provide neuroprotection against excitatory and inflammatory stimuli. These properties raise the possibility that increasing levels of NA in the central nervous system (CNS) could provide benefit in neurological diseases and conditions containing an inflammatory component. In the current study, we tested this possibility by examining the consequences of selectively modulating CNS NA levels on the development of clinical signs in experimental autoimmune encephalomyelitis (EAE). In mice immunized with myelin oligodendrocyte glycoprotein peptide to develop a chronic disease, pretreatment to selectively deplete CNS NA levels exacerbated clinical scores. Elevation of NA levels using the selective NA reuptake inhibitor atomoxetine did not affect clinical scores, while treatment of immunized mice with the synthetic NA precursor L-threo-3,4-dihydroxyphenylserine (L-DOPS) prevented further worsening. In contrast, treatment of mice with a combination of atomoxetine and L-DOPS led to significant improvement in clinical scores as compared to the control group. The combined treatment reduced astrocyte activation in the molecular layer of the cerebellum as assessed by staining for glial fibrillary protein but did not affect Th1 or Th17 type cytokine production from splenic T cells. These data suggest that selective elevation of CNS NA levels could provide benefit in EAE and multiple sclerosis without influencing peripheral immune responses.
authors: Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL 60612, USA.
authors: Maria Vittoria
authors: MV
authors: Simonini
authors: Paul E
authors: PE
authors: Polak
authors: Anthony
authors: A
authors: Sharp
authors: Susan
authors: S
authors: McGuire
authors: Elena
authors: E
authors: Galea
authors: Douglas L
authors: DL
authors: Feinstein
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D001253:Astrocytes / Q000187:drug effects; D000069445:Atomoxetine Hydrochloride; D001545:Benserazide / Q000494:pharmacology; D001596:Benzylamines / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects; D002490:Central Nervous System / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D015259:Dopamine Agents / Q000378:metabolism / Q000494:pharmacology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D007150:Immunohistochemistry; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D009638:Norepinephrine / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D011437:Propylamines / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism
chemical_list: D018759:Adrenergic Uptake Inhibitors; D001596:Benzylamines; D016207:Cytokines; D015259:Dopamine Agents; D005904:Glial Fibrillary Acidic Protein; D011437:Propylamines; D007980:Levodopa; D000069445:Atomoxetine Hydrochloride; D001545:Benserazide; C012102:DSP 4; D009638:Norepinephrine